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SODIUM VALPROATE, POLYCYSTIC OVARY
SYNDROME AND THE NEED FOR A
PROSPECTIVE STUDY
EDITOR — We welcome the publication of Best
Practice Guidelines for the Management of Women
with Epilepsy1. The Guidelines raise some important
issues and will hopefully help to improve manage-
ment standards. Unfortunately, the section discussing
treatment issues and menstrual irregularities contains
some important inaccuracies. Like many recent publi-
cations, the Guidelines do not differentiate between a
polycystic ovarian morphology (PCO) and polycystic
ovary syndrome (PCOS).
PCO can be detected with ultrasound and is found
in 22–33% of the adult female population in the UK2.
When PCO is associated with elevated androgen lev-
els, luteinizing hormone concentrations or any clinical
symptoms of androgen excess it becomes polycystic
ovary syndrome (PCOS). Estimates of the prevalence
of PCOS vary from 5 to 26% of adult women3. PCO
and PCOS are more common in obese women.
It is untrue that the retrospective study published by
Isojarvi et al. in 1996 noted an incidence of PCOS of
64% (14/22) in valproate-treated women. Isojarvi et
al. combined women with hyperandrogenism without
polycystic ovaries on ultrasound (PCO) and women
with PCO without hyperandrogenism to reach the
figure of 64%4. Whilst the definition of polycystic
ovary syndrome (PCOS) may be a disputed issue3, Iso-
jarvi et al. never indicated how many women with
PCOS (by anyone’s definition) they actually found.
The same is true for the 1993 study5 which describes
the same valproate-treated patients as the 1996 paper.
What is more, Isojarvi et al. never published the pre-
treatment body mass indices (BMIs) of the women
described in the two studies. It is possible that the
valproate-treated group had higher pre-anticonvulsant
BMIs that the carbamazepine-treated group and was
therefore at higher risk of PCO, PCOS or hyperandro-
genism. We do not think that the situation was clar-
ified by the (in fact) uncontrolled prospective study
in which women with PCOS (PCO and hyperandro-
genism) were switched from valproate to lamotrigine6.
Further doubt about the findings of Isojarvi et al. were
raised by two recent retrospective studies which did
not find any increased incidence of PCO in valproate-
treated women7, 8.
We feel strongly that the issues surrounding the pos-
sible hormonal and metabolic side effects of valproate
can only be resolved in an appropriately powered,
prospective, randomized-controlled trial. The multi-
centre APOS study (anticonvulsants and polycystic
ovary syndrome) has been designed to this end. This
project is an ‘add-on’ protocol to the study of ‘stan-
dard and new anticonvulsant drugs’ (SANAD). APOS
and SANAD together should finally settle the ques-
tions of whether and how commonly valproate causes
unwanted hormonal side effects in women (if so, in
which women), and whether lamotrigine or topiramate
are safe and effective alternatives. We would like all
physicians interested in the resolution of these im-
portant issues to join the authors in the APOS and
SANAD projects.
Markus Reuber & Peter J Goulding for the APOS
investigators.
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EDITORIAL COMMENT
Reuber and Gouldings’ comments about the Best
Practice Guidelines are well taken. Isojarvi’s two pa-
pers are muddled in the differentiation between merely
possessing polycystic ovaries and having the full syn-
drome and statistics in the second paper are conflated
by patients already included in the first series. The au-
thors of the Guidelines did, however, carefully differ-
entiate between the condition and the syndrome using
the European rather than the American criteria1. Be-
cause of doubts about the Isojarvi results, the authors
merely concluded ‘the condition (PCOS) is thought to
be more common in women taking valproate’. Like
Reuber and Goulding, we await the outcome of more
definitive studies but would point out that not all au-
thorities make a sharp distinction between the condi-
tion and the syndrome, but suggest there may well be a
continuum between the two: women may well develop
polycystic ovaries in childhood or adolescence (due,
possibly to a genetic predisposition): whether they
then develop the syndrome may depend on other fac-
tors1 which include later weight gain or hyperinsuli-
naemia (both thought to be associated with the use of
valproate). It is possible that there is a sub-population
of girls with epilepsy who, already possessing poly-
cystic ovaries, are particularly vulnerable to develop-
ing the polycystic ovary syndrome either because of
their epilepsy or because of the medication they take. It
would be important to identify them before treatment
if this hypothesis is true, and we hope that the APOS
study helps to clarify the extent of the problem. How-
ever, there may be other reasons for avoiding valproate
(unless clinically essential) in women of child-bearing
potential particularly its known teratogenicity2.
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